By Fineline Cube 
Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer’s disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option — a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer’s disease.
Regulatory & Launch Timeline
| Date | Milestone |
|---|---|
| 2025 | Approval and launch of the maintenance therapy indication for early AD |
| Jul 2026 | US approval of LEQEMBI IQLIK for initial treatment of early AD |
| 01 Sep 2026 | US launch of LEQEMBI IQLIK subcutaneous auto-injector for initial treatment of early AD |
Drug Profile & Administration
- Molecule: Lecanemab, an anti-amyloid monoclonal antibody for early Alzheimer’s disease
- Formulation: LEQEMBI IQLIK — subcutaneous auto-injector, replacing intravenous infusion for eligible patients
- Patient Benefits: Reduced administration time versus IV infusion and the option for at-home dosing, lowering the treatment burden on patients and caregivers
- Coverage Across Treatment Journey: With initial treatment (2026 approval) and maintenance therapy (2025 approval) indications, LEQEMBI IQLIK spans the full treatment arc of early AD
Eisai–Biogen Collaboration Structure
| Item | Detail |
|---|---|
| Partners | Eisai Co., Ltd. and Biogen |
| Global Development & Regulatory Submissions | Eisai (lead responsibility) |
| Commercialization | Co-commercialized by both companies |
| Final Decision-Making Authority | Eisai |
Market Impact & Outlook
- Access Expansion: At-home subcutaneous dosing removes a major adoption barrier for LEQEMBI — repeated IV infusions — potentially widening the addressable early-AD patient population in the United States
- Franchise Durability: The full-indication arc from initial treatment through maintenance therapy strengthens LEQEMBI‘s position as a complete, long-term treatment platform rather than a single intervention
- Competitive Positioning: As amyloid-directed therapies compete for diagnosis-driven market share, administration convenience becomes a decisive differentiator for Eisai and Biogen against rival anti-amyloid programs
- Infrastructure Shift: Home dosing could reduce dependence on infusion-center capacity, easing healthcare-system bottlenecks that have constrained Alzheimer’s treatment volume
- Catalyst Watch: Early uptake metrics, real-world adherence under home administration, and payer coverage policies will define the commercial trajectory of LEQEMBI IQLIK
Forward‑Looking Statements — This brief contains forward-looking statements regarding product launch, market adoption, and commercial potential that involve risks and uncertainties. Actual results may differ materially. Nothing herein constitutes investment advice.-Fineline Info & Tech